Last reviewed · How we verify

A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes

NCT02806973 Phase 1 COMPLETED Results posted

This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant. The study is open to adults with type 1 or type 2 diabetes and will last about 50 days.

Details

Lead sponsorEli Lilly and Company
PhasePhase 1
StatusCOMPLETED
Enrolment32
Start date2015-01
Completion2015-04

Conditions

Interventions

Primary outcomes

Countries

Canada